Literature DB >> 9214419

Preliminary definition of improvement in juvenile arthritis.

E H Giannini1, N Ruperto, A Ravelli, D J Lovell, D T Felson, A Martini.   

Abstract

OBJECTIVE: To identify a core set of outcome variables for the assessment of children with juvenile arthritis (JA), to use the core set to develop a definition of improvement to determine whether individual patients demonstrate clinically important improvement, and to promote this definition as a single efficacy measure in JA clinical trials.
METHODS: A core set of outcome variables was established using a combination of statistical and consensus formation techniques. Variables in the core set consisted of 1) physician global assessment of disease activity; 2) parent/patient assessment of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) number of joints with limited range of motion; and 6) erythrocyte sedimentation rate. To establish a definition of improvement using this core set, 21 pediatric rheumatologists from 14 countries met, and, using consensus formation techniques, scored each of 72 patient profiles as improved or not improved. Using the physicians' consensus as the gold standard, the chi-square, sensitivity, and specificity were calculated for each of 240 possible definitions of improvement. Definitions with sensitivity or specificity of <80% were eliminated. The ability of the remaining definitions to discriminate between the effects of active agent and those of placebo, using actual trial data, was then observed. Each definition was also ranked for face validity, and the sum of the ranks was then multiplied by the kappa statistic.
RESULTS: The definition of improvement with the highest final score was as follows: at least 30% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by >30%. The second highest scoring definition was closely related to the first; the third highest was similar to the Paulus criteria used in adult rheumatoid arthritis trials, except with different variables. This indicates convergent validity of the process used.
CONCLUSION: We propose a definition of improvement for JA. Use of a uniform definition will help standardize the conduct and reporting of clinical trials, and should help practitioners decide if a child with JA has responded adequately to therapy. We are in the process of prospectively validating this definition and several others that scored highly.

Entities:  

Mesh:

Year:  1997        PMID: 9214419     DOI: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  317 in total

Review 1.  Autologous haematopoietic stem cell transplantation in juvenile idiopathic arthritis.

Authors:  L R Wedderburn; M Abinun; P Palmer; H E Foster
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 2.  Outcome measures and medical progress: why outcome measures are needed in childhood arthritis.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 3.  Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

Authors:  Simon Tarp; Gil Amarilyo; Ivan Foeldvari; Robin Christensen; Jennifer M P Woo; Neta Cohen; Tracy D Pope; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2015-11-30       Impact factor: 7.580

Review 4.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

5.  Prominent midfoot involvement in children with enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  Sanat Phatak; Namita Mohindra; Abhishek Zanwar; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2017-06-20       Impact factor: 2.980

6.  PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it.

Authors:  N Ruperto; P Garcia-Munitis; L Villa; M Pesce; A Aggarwal; A Fasth; T Avcin; S-C Bae; Z Balogh; C Li; J De Inocencio; M Dibra; P Dolezalova; Y El Miedany; B Flato; M Harjacek; H-I Huppertz; F Kanakoudi-Tsakalidou; N Wulffraat; P Lahdenne; J A Melo-Gomes; D Mihaylova; S Nielsen; I Nikishina; H Ozdogan; K Pagava; V Panaviene; A-M Prieur; A-M Romicka; I Rumba; N Shafaie; G Susic; S Takei; Y Uziel; R Vesely; P Woo; A Martini
Journal:  Ann Rheum Dis       Date:  2005-03-10       Impact factor: 19.103

Review 7.  Update on the medical treatment of juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.592

8.  Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study.

Authors:  Femke H M Prince; Marinka Twilt; Nelleke C J A Jansen-Wijngaarden; Lisette W A van Suijlekom-Smit
Journal:  Ann Rheum Dis       Date:  2007-02-26       Impact factor: 19.103

9.  Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis.

Authors:  K Bendtzen; P R Hansen; K Rieneck
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

10.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.